Acute Graft-Versus-Host Disease: A Brief Review

Göker, Hakan; Aladag, Elifcan; Kelkitli, Engin

doi:10.4274/tjh.galenos.2019.2019.0157

Acute Graft-Versus-Host Disease: A Brief Review

Elifcan ALADAĞ, (Hacettepe Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Engin KELKİTLİ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Samsun, Türkiye)

Hakan GÖKER (Hacettepe Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Turkish Journal of Hematology

4 0

Yıl: 2020 Cilt: 37 Sayı: 1 Sayfa Aralığı: 1 - 4 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2019.2019.0157 İndeks Tarihi: 16-10-2020

Acute Graft-Versus-Host Disease: A Brief Review

Öz:

Graft‐versus‐host disease (GvHD) is an important complication that can be observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Acute GvHD (aGvHD) is seen after alloHSCT and the incidence of aGvHD is around 30%-50%. aGvHD prophylaxis is essential in patients undergoing allo-HSCT. Initial therapy for aGvHD is steroids. Prognosis is poor in aGvHD patients not responding to steroids. In this article, the pathobiology, clinical findings, prophylaxis, and treatment of aGvHD will be summarized.

Anahtar Kelime:

Akut Graft Versus Host Hastalığı: Kısa Bir Derleme

Öz:

Akut graft‐versus‐host hastalığı (GvHD), allojeneik hematopoetik kök hücre nakli (alloHKHN) sonrasında görülebilen önemli bir komplikasyondur. Akut GvHD (aGvHD) insidansı yaklaşık %30-50 oranında görülmektedir. AlloHKHN yapılan hastalarda GvHD proflaksisi önemlidir. aGvHD gelişen hastalarda başlangıç tedavisi steroiddir. Steroide yanıtsız aGvHD’de prognoz kötüdür. Bu yazıda aGvHD patobiyolojisi, klinik bulguları, profilaksisi ve tedavisi özetlenecektir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, UrbanoIspizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012;119:296-307.
2. Lee SE, Cho BS, Kim JH, Yoon JH, Shin SH, Yahng SA, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant 2013;48:587-592.
3. Chao NJ. Graft-versus-host disease: the viewpoint from the donor T cell. Biol Blood Marrow Transplant 1997;3:1-10.
4. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001;29:259-277.
5. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966;62:21-78.
6. Toubai T, Mathewson ND, Magenau J, Reddy P. Danger signals and graftversus-host disease: current understanding and future perspectives. Front Immunol 2016;7:539.
7. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
8. Ali AM, DiPersio JF, Schroeder MA. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review. Biol Blood Marrow Transplant 2016;22:1552-1564.
9. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014;49:168-173.
10. Ram R, Storb R. Pharmacologic prophylaxis regimens for acute graft-versushost disease: past, present and future. Leuk Lymphoma 2013;54:1591-1601.
11. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-2314.
12. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versushost disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-2068.
13. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993;329:1225-1230.
14. Hoyt R, Ritchie DS, Roberts AW, MacGregor L, Curtis DJ, Szer J, Grigg AP. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Bone Marrow Transplant 2008;41:651-658.
15. Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ. Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graftversus-host disease after haploidentical transplantation. J Clin Oncol 2016;34:1855-1863.
16. Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, Sorasio R, Massi D, Van Lint MT, Raiola AM, Gualandi F, Selleri C, Sormani MP, Signori A, Risitano A, Bonifazi F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. Haematologica 2017;102:2125-2133.
17. Rashidi A, DiPersio JF, Sandmaier BM, Colditz GA, Weisdorf DJ. Steroids versus steroids plus additional agent in frontline treatment of acute graftversus-host disease: a systematic review and meta-analysis of randomized trials. Biol Blood Marrow Transplant 2016;22:1133-1137.
18. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015;29:2062-2068.
19. Bredeson C, Rumble RB, Varela NP, Kuruvilla J, Kouroukis CT; Stem Cell Transplant Steering Committee. Extracorporeal photopheresis in the management of graft-versus-host disease. Curr Oncol 2014;21:e310-325.
20. McMurray RW, Harisdangkul V. Mycophenolate mofetil: selective T cell inhibition. Am J Med Sci 2002;323:194-196.
21. Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, Antin JH. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008;14:920-926.
22. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014;124:1372-1377.
23. Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115:3224-3230.
24. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, Itälä-Remes M, Blaise D, Meijer E, Koc Y, Milpied N, Schouten HC, Kroeger N, Mohty M, Nagler A. Post-transplant cyclophosphamide for graft-versushost disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWPEBMT. J Hematol Oncol 2018;11:40.
25. Arai Y, Jo T, Matsui H, Kondo T, Takaori-Kondo A. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma 2017;58:1840-1848.
26. Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev 2012:CD009159.
27. Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP 3rd. Bortezomibbased graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012;30:3202-3208.
28. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001;113:807-813.
29. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL. Etanercept plus methylprednisolone as initial therapy for acute graftversus-host disease. Blood 2008;111:2470-2475.

APA	Aladag E, Kelkitli E, Göker H (2020). Acute Graft-Versus-Host Disease: A Brief Review. , 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
Chicago	Aladag Elifcan,Kelkitli Engin,Göker Hakan Acute Graft-Versus-Host Disease: A Brief Review. (2020): 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
MLA	Aladag Elifcan,Kelkitli Engin,Göker Hakan Acute Graft-Versus-Host Disease: A Brief Review. , 2020, ss.1 - 4. 10.4274/tjh.galenos.2019.2019.0157
AMA	Aladag E,Kelkitli E,Göker H Acute Graft-Versus-Host Disease: A Brief Review. . 2020; 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
Vancouver	Aladag E,Kelkitli E,Göker H Acute Graft-Versus-Host Disease: A Brief Review. . 2020; 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
IEEE	Aladag E,Kelkitli E,Göker H "Acute Graft-Versus-Host Disease: A Brief Review." , ss.1 - 4, 2020. 10.4274/tjh.galenos.2019.2019.0157
ISNAD	Aladag, Elifcan vd. "Acute Graft-Versus-Host Disease: A Brief Review". (2020), 1-4. https://doi.org/10.4274/tjh.galenos.2019.2019.0157

APA	Aladag E, Kelkitli E, Göker H (2020). Acute Graft-Versus-Host Disease: A Brief Review. Turkish Journal of Hematology, 37(1), 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
Chicago	Aladag Elifcan,Kelkitli Engin,Göker Hakan Acute Graft-Versus-Host Disease: A Brief Review. Turkish Journal of Hematology 37, no.1 (2020): 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
MLA	Aladag Elifcan,Kelkitli Engin,Göker Hakan Acute Graft-Versus-Host Disease: A Brief Review. Turkish Journal of Hematology, vol.37, no.1, 2020, ss.1 - 4. 10.4274/tjh.galenos.2019.2019.0157
AMA	Aladag E,Kelkitli E,Göker H Acute Graft-Versus-Host Disease: A Brief Review. Turkish Journal of Hematology. 2020; 37(1): 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
Vancouver	Aladag E,Kelkitli E,Göker H Acute Graft-Versus-Host Disease: A Brief Review. Turkish Journal of Hematology. 2020; 37(1): 1 - 4. 10.4274/tjh.galenos.2019.2019.0157
IEEE	Aladag E,Kelkitli E,Göker H "Acute Graft-Versus-Host Disease: A Brief Review." Turkish Journal of Hematology, 37, ss.1 - 4, 2020. 10.4274/tjh.galenos.2019.2019.0157
ISNAD	Aladag, Elifcan vd. "Acute Graft-Versus-Host Disease: A Brief Review". Turkish Journal of Hematology 37/1 (2020), 1-4. https://doi.org/10.4274/tjh.galenos.2019.2019.0157